Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.19.3.a.u2
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
12 Months Ended
Dec. 31, 2019
USD ($)
reportingUnit
segment
Dec. 31, 2018
USD ($)
segment
reportingUnit
Dec. 31, 2017
USD ($)
segment
Jan. 01, 2019
USD ($)
Accounting Policies [Line Items]        
Number of operating segments | segment 2 2 1  
Advertising expense $ 500,000 $ 500,000 $ 700,000  
Cash and cash equivalents 90,498,000 53,039,000 31,219,000  
Cash and cash equivalents, adjusted cost 90,498,000 53,039,000 31,219,000  
Cash 19,300,000 21,800,000    
Money market funds 71,200,000 31,200,000    
Assets Held-in-trust 700,000 700,000    
Unbilled contracts receivable 10,100,000 2,700,000    
Impairment of long-lived assets held-for-use $ 0 $ 0 $ 0  
Number of reporting units 2 2 1  
Goodwill $ 3,241,000 $ 3,241,000    
Goodwill impairment $ 0 0 $ 0  
Operating lease, weighted average discount rate, percent 6.60%     6.60%
Finance lease, weighted average discount rate, percent 5.00%     5.00%
Provision for (benefit from) income taxes $ 17,000 (37,000) $ 81,000  
Operating lease, right-of-use asset 23,837,000 0    
Lease obligations 26,058,000 0    
Finance lease, right-of-use asset 268,000 0   $ 500,000
Finance lease, liability $ 60,000 0   300,000
Accounting Standards Update 2018-01        
Accounting Policies [Line Items]        
Operating lease, right-of-use asset       26,600,000
Lease obligations       $ 27,600,000
Novel Biotherapeutics        
Accounting Policies [Line Items]        
Goodwill, allocation percent 24.00%      
Goodwill $ 800,000      
Performance Enzymes        
Accounting Policies [Line Items]        
Goodwill, allocation percent 76.00%      
Goodwill $ 2,400,000      
Demand Deposits | Letter of Credit        
Accounting Policies [Line Items]        
Restricted cash and investments, noncurrent $ 1,100,000 $ 700,000